Manufacturing advantages of multi-drug facilities continue to influence pharmaceutical companies towards meeting the growing demands by using the same facility to produce different drugs. In such facilities, single-use bioreactors are essential commodities that provide flexibility in the production of multiple drugs. By consuming minimum costs and saving time, single-use bioreactors can maintain the quality of drug production and eliminate the downtime caused by line clearance and cleaning validation. Their role in increasing the batch production of different drugs within a specific time period continues to drive the global adoption of single-use bioreactors.
According to the latest report published by Transparency Market Research, the key role of single-use bioreactors in boosting the production of pharmaceuticals is anticipated to drive their demand in the approaching years. During the forecast period, 2017-2026, the global market for single-use bioreactors is anticipated to incur robust expansion at 13.5% CAGR, raking in over US$ 1.5 Bn revenues by the end of 2026. With nearly two-fifth revenue share, Europe is anticipated to represent the leading region in the global single-use bioreactors market in 2017. North America and the Asia-Pacific excluding Japan (APEJ) region are also anticipated to be at the forefront of global single-use bioreactor market expansion.
Increasing Sales of Single-Use Bioreactor Systems and Media Bags
The report projects that in 2017, the top-selling products in the global single-use bioreactors market will be observed to be single-use bioreactor systems and media bags. Collectively, these products will account for more than half of revenues procured in the global market. Towards 2026, the demand for filtration assemblies is anticipated to gain steady traction.
A majority of products sold in the global single-use bioreactors market will be used to preserve & carry mammalian cells and bacterial cells. Increasing significance of single-use bioreactors in the transfer of bacterial cells and mammalian cells during production of biopharmaceuticals will continue to fuel the growth of the global market. By 2026, over 85% of the global single-use bioreactors market revenues will be accounted by mammalian and bacterial cells, together.
Biopharmaceutical Companies to Represent Largest End-users
Through 2026, biopharmaceutical companies are pegged to account for largest revenue share as end-users in the global single-use bioreactors market. A majority of single-use bioreactor products being manufactured in the global market throughout the forecast period will be used by biopharmaceutical companies, creating an absolute dollar opportunity of over US$ 720 Mn between 2017 and 2026.
Furthermore, the report has also analysed the global single-use bioreactors market on the basis of types of molecules. In 2017, single-use bioreactors worth nearly US$ 100 Mn will be sold for their use in dispensing vaccine molecules during drug production. The study also reveals that the use of single-use bioreactors in stem cell transplant will gain traction in the upcoming years.
Use of single-use bioreactors is being largely prompted by commercial considerations over technological concerns. Manufacturers of such disposable bioreactors are focusing on increasing the role of single-use bioreactors in enabling biopharmaceutical companies towards cost-savings. While single-use bioreactor bags are creating secure pathways in production of protein-based drugs, the compounds or materials in them are tending to leak due to the extrusion process that makes the bag films thin. Several companies in the global single-use bioreactors market are focusing on stabilizing these materials for avoiding the risks associated with malfunctioning single-use bioreactors. Companies namely, Eppendorf, Pierre Guerin, Sartorius Stedim Biotech , Solida Biotech, Merck Millipore, Distek, GE Healthcare, PBS Biotech, Danaher, Celltainer Biotech, Thermo Fisher Scientific, Cellexus, Parker Hannifin, Cesco Bioengineering, and Applikon Biotechnology are observed as the leading manufacturers of single-use bioreactors, and are expected to remain
Global Single-Use Bioreactors Market: Overview
Single-use bioreactors are being used on a large scale in today’s biotechnology manufacturing facility. Moreover, there has also been a significant growth in the use of single-use bioreactors in the pharmaceutical industry across the globe. The use is increasing as they provide immense flexibility to the pharmaceutical companies. Single-use bioreactor helps in mitigating the risk of cross-contamination, especially during the production of multi-drugs at pharmaceutical manufacturing units. This is helping the pharmaceutical companies save time and also leads to the significant cost saving. Due to these factors, there has been a high preference for single-use bioreactors.
The single-use bioreactor is expected to play a crucial role in the pharmaceutical industry, resulting in the rapid development of a new variety of drugs that will help in treating various diseases that are currently untreatable and becoming more prevalent. Manufacturers are focusing on introducing high-power single-use bioreactors and the control systems are also being improved to help in multiple unit operations. New systems are also being designed specifically for microbial fermentation.
Global Single-Use Bioreactors Market: Research Methodology
The report on the global single-use bioreactor market offers an overview of the present market state and also provides insights on the future growth of the market and key segments for the forecast period between 2017 and 2026. The report also offers an in-depth analysis of the market dynamics including trends, drivers, challenges, opportunities, and regulatory framework of the global market. These market dynamics are expected to have an influence on the future growth prospects of the market.
The report offers both quantitative and qualitative data analysis based on primary as well as secondary research. The report also provides an analysis of various elements in the market based on Porter’s five forces analysis, SWOT analysis, and analysis on market attractiveness. Various tools are used for validating gathered data and insights that are expected to significantly influence the business decision making process.
The report also talks about the key microeconomic and macroeconomic factors that are likely to have an impact on the overall development of the market during the forecast period between 2017 and 2026. All the data provided by the report can help the companies in formulating the growth strategies for earning better returns in the global single-use bioreactors market.
Global Single-Use Bioreactors Market: Market Segmentation
The global single-use bioreactors market is segmented on the basis of product type, end user, cells type, molecule type, and region. On the basis of product type, the market is segmented into single use bioreactor systems, media bags, filtration assemblies, and other products. On the basis of end user, the segment includes biopharmaceutical companies, biotechnology companies and other end users. By cells type, the market is segmented into mammalian cells, bacterial cells, yeast cells and other cells. By molecule type, the market is segmented into monoclonal antibodies (MABS), vaccines, stem cells, gene-modified cells and other molecules.
Region-wise, the global single use bioreactor market is segmented into Europe, North America, Asia Pacific Excluding Japan (APEJ), Latin America, Japan, and the Middle East and Africa (MEA). The report provides forecast, revenue share, and market size for each segment as well as for each region for 2017 to 2026. The data is provided in the form of US$ Mn and CAGR in percent form.
Global Single-Use Bioreactors Market: Competitive Landscape
The report provides detailed analysis of some of the leading market players in the global single-use bioreactors market such as Sartorius Stedim Biotech, Merck Millipore, GE Healthcare, Danaher, Thermo Fisher Scientific, Parker Hannifin, Applikon Biotechnology, Eppendorf, Cesco Bioengineering, Cellexus, Celltainer Biotech, PBS Biotech, Distek, Solida Biotech, and Pierre Guerin. All of the leading players in the market are evaluated on parameters including product portfolio, company overview, strategies, financial overview, and latest developments.